blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4074732

EP4074732 - FULLY HUMAN ANTIBODIES AGAINST OX40, METHOD FOR PREPARING THE SAME, AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  07.04.2023
Database last updated on 13.09.2024
FormerThe application has been published
Status updated on  16.09.2022
Most recent event   Tooltip28.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Wuxi Biologics (Shanghai) Co. Ltd.
No. 299 Fute Zhong Road
Pudong New District
Shanghai 200131 / CN
For all designated states
Wuxi Biologics Ireland Limited
One Spencer Dock
North Wall Quay
Dublin 1 / IE
[2022/42]
Inventor(s)01 / ZHENG, Yong
Shanghai, 200131 / CN
02 / YANG, Baotian
Shanghai, 200131 / CN
03 / LI, Jing
Shanghai, 200131 / CN
 [2022/42]
Representative(s)Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
[2022/42]
Application number, filing date22174660.507.05.2019
[2022/42]
Priority number, dateWO2018CN8657411.05.2018         Original published format: PCT/CN2018/086574
CN20181052984029.05.2018         Original published format: CN201810529840
[2022/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4074732
Date:19.10.2022
Language:EN
[2022/42]
Search report(s)(Supplementary) European search report - dispatched on:EP12.09.2022
ClassificationIPC:C07K16/28, A61K39/395, A61P35/00, A61P37/00, A61P31/00
[2022/42]
CPC:
A61P29/00 (EP,KR); C07K16/2875 (KR); C07K16/2878 (EP,CN,US);
A61P31/00 (EP); A61P35/00 (EP,KR); A61P35/04 (US);
A61P37/00 (EP); A61P37/02 (EP); C12N5/163 (EP);
A01K2227/105 (EP); A01K2267/0331 (EP); A61K2039/505 (EP,KR,US);
C07K2317/21 (EP,KR,US); C07K2317/33 (EP,KR,US); C07K2317/34 (EP,KR);
C07K2317/52 (US); C07K2317/56 (CN); C07K2317/565 (CN,KR,US);
C07K2317/732 (EP,US); C07K2317/734 (EP,KR,US); C07K2317/75 (EP);
C07K2317/76 (KR,US); C07K2317/92 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/19]
Former [2022/42]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VOLLSTÄNDIG MENSCHLICHE ANTIKÖRPER GEGEN OX40, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG[2022/42]
English:FULLY HUMAN ANTIBODIES AGAINST OX40, METHOD FOR PREPARING THE SAME, AND USE THEREOF[2022/42]
French:ANTICORPS ENTIÈREMENT HUMAINS DIRIGÉS CONTRE OX40, MÉTHODE DE PRÉPARATION CORRESPONDANT ET UTILISATION ASSOCIÉE[2022/42]
Examination procedure06.04.2023Amendment by applicant (claims and/or description)
06.04.2023Examination requested  [2023/19]
06.04.2023Date on which the examining division has become responsible
Parent application(s)   TooltipEP19799456.9  / EP3790903
Fees paidRenewal fee
20.05.2022Renewal fee patent year 03
20.05.2022Renewal fee patent year 04
08.03.2023Renewal fee patent year 05
28.05.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO03106498  (CRUCELL HOLLAND BV [NL], et al) [I] 1-12 * examples 6-7 *;
 [I]WO2009079335  (MEDAREX INC [US], et al) [I] 1-12 * example 1 * * page 52, paragraph 0172 * * page 53, paragraph 0177 - paragraph 0178 * * page 54, paragraph 0182 * * page 55, paragraph 0188 - page 56, paragraph 0192 *;
 [I]WO2012027328  (UNIV TEXAS [US], et al) [I] 1-12 * paragraph [0146] * * figure 20 * * page 7' - page 71; example V *;
 [I]WO2014148895  (BIOCEROX PROD BV [NL], et al) [I] 1-12 * page 34, line 12 - line 14 *;
 [I]WO2015153513  (GENENTECH INC [US], et al) [I] 1-12 * page 126, column 0446 * * page 134, paragraph 0462 * * page 134; table 2 *;
 [I]WO2016179517  (AGENUS INC [US], et al) [I] 1-12 * example 1 * * paragraph [0449] * * page 172, paragraph 0457 * * figure 2C * * paragraph [0479] *;
 [I]WO2016185016  (ALLIGATOR BIOSCIENCE AB [SE]) [I] 1-12 * examples 3, 6-7 * * tables 3.1, 6.1 * * figure 8 *;
 [I]WO2017063162  (DINGFU BIOTARGET CO LTD [CN]) [I] 1-12 * page 24; table 3 * * figure 7 * * examples 9, 12 *;
 [I]US2018044427  (ARMSTRONG ANTHONY [US], et al) [I] 1-12 * paragraph [0468] * * table 3 * * example 4 * * paragraph [0483] - paragraph [0484] * * example 5 *;
 [A]  - WILLOUGHBY JANE ET AL, "OX40: Structure and function - What questions remain?", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20170113), vol. 83, doi:10.1016/J.MOLIMM.2017.01.006, ISSN 0161-5890, pages 13 - 22, XP029925307 [A] 1-12 * page 19, column l, paragraph 5 *

DOI:   http://dx.doi.org/10.1016/j.molimm.2017.01.006
by applicantUS4399216
 US4634665
 WO8704462
 WO8901036
 EP0338841
 US5179017
 US5500362
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 US5750373
 US5821337
 US6075181
 US6150584
 WO03048731
 WO03106498
 US8236930
 WO2014093908
 WO2014148895
 US2014308276
 WO2015153513
 WO2016057667
 WO2016179517
 WO2016185016
 WO2017063162
 US2018044427
    - BEERS et al., Clin. Can. Res., (20000000), vol. 6, pages 2835 - 43
    - CLYNES et al., PNAS (USA, (19980000), vol. 95, pages 652 - 656
    - CHOTHIALESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 878 - 883
    - SAMBROOK et al., Molecular Cloning: A laboratory Manual, Cold Spring Harbor Laboratory Press, (19890000), pages 47 - 51
    - "Genbank", Database accession no. XP _001090870.1
    - GAZZANO-SANTORO et al., J. Immunol. Methods, (19960000), vol. 202, page 163
    - CARILLO et al., SIAMJ. Applied Math., (19880000), vol. 48, page 1073
    - JONSSON, U. et al., Ann. Biol. Clin., (19930000), vol. 51, pages 19 - 26
    - Computer Analysis of Sequence Data, John Wiley & Sons, (19940000), pages 3 - 10
    - JONSSON, U. et al., Biotechniques, (19910000), vol. 11, pages 620 - 627
    - GRAHAM et al., Virology, (19730000), vol. 52, page 456
    - CHU et al., Gene, (19810000), vol. 13, page 197
    - JOHNSSON, B. et al., J. Mol. Recognit., (19950000), vol. 8, pages 125 - 131
    - JOHNNSON, B. et al., Anal. Biochem., (19910000), vol. 198, pages 268 - 277
    - RAVETCHKINET, Annu. Rev. Immunol, (19910000), vol. 9, pages 457 - 92
    - LONBERGHUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - BARBAS et al., Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, pages 7978 - 7982
    - MORRISON, S., Science, (19850000), vol. 229, page 1202
    - BOERNER et al., J. Immunol, (19910000), vol. 147, no. 1, pages 86 - 95
    - TAKEBE et al., Mol. Cell. Biol., (19880000), vol. 8, pages 466 - 472
    - HAMMERLING et al., Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, (19810000), pages 563 - 681
    - "Gene Expression Technology", GOEDDEL, Methods in Enzymology, Academic Press, (19900000), page 185
    - URLAUBCHASIN, Proc. Natl. Acad. ScL USA, (19800000), vol. 77, pages 4216 - 4220
    - R. J. KAUFMANP. A. SHARP, J. Mol. Biol., (19820000), vol. 159, pages 601 - 621
    - RETTER et al., Nucl. Acids Res, (20050000), vol. 33, pages D671 - D674
    - "Protein Sequence and Structure Analysis of Antibody Variable Domains", DR. ANDREW C. R., Antibody Engineering Lab Manual, Springer-Verlag
    - E. MEYERSW. MILLER, Comput. Appl. Biosci., (19880000), vol. 4, pages 11 - 17
    - NEEDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, pages 444 - 453
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 10
    - ALTSCHUL et al., Nucleic Acids Res, (19970000), vol. 25, no. 17, pages 3389 - 3402
    - BRUMMELL et al., Biochem, (19930000), vol. 32, pages 1180 - 1187
    - KOBAYASHI et al., Protein Eng, (19990000), vol. 12, no. 10, pages 879 - 884
    - BURKS et al., Proc. Natl. Acad. Sci. USA, (19970000), vol. 94, pages 412 - 417
    - DE WILDT et al., Prot. Eng., (19970000), vol. 10, pages 835 - 41
    - KOMISSAROV et al., J. Biol. Chem., (19970000), vol. 272, pages 26864 - 26870
    - HALL et al., J. Immunol., (19920000), vol. 149, pages 1605 - 12
    - KELLEYO' CONNELL, Biochem., (19930000), vol. 32, pages 6862 - 35
    - ADIB-CONQUY et al., Int. Immunol., (19980000), vol. 10, pages 341 - 6
    - REINEKE, Methods Mol Biol, (20040000), vol. 248, pages 443 - 63
    - TOMER, Protein Science, (20000000), vol. 9, pages 487 - 496
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.